5100 Xizang Glacier Company Limited Announces Academic Collaboration with HKU on Clinical Research of Mineral Water’s Effects on Hyperuricemia

Key Highlights:

• 5100 Xizang Glacier Company Limited (“5100” or the “Company”) has entered into a Memorandum of Understanding (MOU) with a research team led by Professor Yibin FENG at the School of Chinese Medicine, The University of Hong Kong (HKU), to conduct collaborative academic research.
• The research will evaluate the clinical efficacy of “5100” Xizang Glacier Mineral Water in patients with hyperuricemia, and explore the mechanistic effects of mineral components on uric acid metabolism and renal excretion.
• This initiative is part of the Company’s strategy to scientifically substantiate health claims for its products, which may have significant implications for regulatory approval and market positioning in Mainland China, Hong Kong, and international markets.

In-Depth Details of the Collaboration

1. Scope and Structure of the Research
The MOU, signed on 27 March 2026, sets out a framework for a multi-faceted clinical research collaboration between Carry Rich Investment Limited (a wholly-owned subsidiary of 5100) and Professor Feng’s team at HKU. The collaboration will include:

• Clinical Research Design and Implementation: The Professor Team will design a randomized, double-blind, controlled clinical trial, set inclusion/exclusion criteria, develop intervention and follow-up protocols, establish outcome indicators, and create a statistical analysis plan. They will also manage ethical approvals and academic supervision.
• Carry Rich will provide “5100” mineral water products, technical materials, and operational support, including subject recruitment, product delivery, and compliance monitoring.
• The study will adhere to international clinical research standards (e.g., ICH-GCP), ensuring scientific rigor and data integrity.

2. Clinical Efficacy and Safety Evaluation
The research will focus on patients with hyperuricemia and assess endpoints such as changes in serum uric acid levels, target attainment rates, renal function, electrolyte levels, and urinary pH. Safety will be closely monitored, with systematic reporting on adverse events such as abdominal distension, diarrhea, and edema. Carry Rich will also be involved in discussions regarding research progress and future product strategies based on the findings.

3. Data Analysis and Dissemination
Professor Feng’s team will manage data analysis and prepare research reports, with the intention to publish results in top-tier international academic journals and conferences. The Parties will jointly explore commercialization opportunities, including integration into clinical guidelines, health management products, and potential regulatory submissions.

4. Further Research and Mechanistic Exploration
Upon completion of the initial study, the Parties may pursue larger, multi-center clinical trials to validate the findings and investigate the mechanisms by which mineral components in the water influence uric acid metabolism and renal excretion. These studies may inform the development of personalized drinking regimens and next-generation health management solutions.

5. Commercial and Strategic Implications
The research data will underpin scientific promotion, health claims substantiation, and regulatory communications for 5100’s products in China, Hong Kong, and global markets. Additionally, the Parties will explore the application of research results in digital health management platforms, AI-based health assessment systems, and public health education initiatives.

Potential Share Price Sensitivity and Investor Considerations

• Potentially Price Sensitive: If successful, this collaboration could significantly strengthen 5100’s scientific credibility and support its health claims, which may lead to enhanced market competitiveness and product differentiation. Positive clinical outcomes and subsequent regulatory acceptance could drive product demand and open new markets, potentially impacting the Company’s share value.
• No Binding Commitment Yet: The MOU is not legally binding and does not guarantee a definitive agreement or commercialization. Investors should note that there remains execution risk, and no assured outcome at this stage.
• Reputational Enhancement: The involvement of a highly cited HKU research team led by Professor Yibin FENG (recognized in Clarivate’s Highly Cited Researchers 2024 and Stanford University’s top 2% scientists) elevates the scientific and reputational profile of the collaboration.
• Strategic Alignment: The initiative aligns with 5100’s ambition to integrate traditional Chinese medicine with modern medical science, enhancing the Group’s R&D and innovation capabilities in the broader healthcare sector.

Professor Team Background

Professor Yibin FENG and his HKU team possess deep expertise in pharmacology, Chinese and integrative medicine, with a strong track record in research on liver, kidney, diabetes, and tumor prevention and treatment. Their participation adds significant scientific credibility to the project.

Term and Effect of the MOU

The MOU is effective from 26 March 2026 to 25 March 2031, but is expressly non-legally binding. Statements regarding the collaboration in company documents do not constitute product endorsement or efficacy warranties by HKU or the Professor Team.

Conclusion

This announcement signals a potentially transformative step for 5100 Xizang Glacier Company Limited as it seeks to validate and commercialize the health benefits of its mineral water products. While the collaboration’s ultimate commercial impact remains contingent on future definitive agreements and clinical outcomes, the partnership with a top HKU research team puts 5100 in a strong position to advance its R&D and regulatory strategy in the health sector.

Disclaimer: This article is for information purposes only and does not constitute investment advice. The Memorandum of Understanding described is not legally binding and there is no guarantee that a definitive agreement or successful outcome will result. Investors should exercise caution and do their own due diligence before making investment decisions.

View 5100 XIZANG Historical chart here